Keyword: Forbion Capital Partners
The haul makes BioDiscovery 5 the largest fund dedicated to biotechs and medical devices in Europe and tees up De Rothschild to invest in 17 firms.
The round reunites some of the executives and investors who helped Dezima and Akarna to takeovers by Amgen and Allergan, respectively.
The big biotech participated in the round to equip Hookipa to advance its cytomegalovirus vaccine and cancer candidate through early clinical testing.
The series B round equips the team that led BioVex to a $1 billion buyout by Amgen to take another crack at developing a cancer-fighting virus.
The series C tees Milestone up to test its intranasal calcium channel blocker etripamil in patients with paroxysmal supraventricular tachycardia.
Argenx’s IPO fundraising total has come to a stop at $144.7 million, more than 50% above its initial target.
Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.
Prexton Therapeutics has raised €29 million ($31 million) to take its Parkinson’s disease candidate through two phase 2 trials.
NeRRe Therapeutics has raised £23 million in a Series B backed by new investors Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.
European biotech Allecra Therapeutics has raised its second load of cash as it looks to push on in the fight against multi-drug resistant gram-negative bacteria.